Project Details
| Status | Active |
|---|---|
| Effective start/end date | 3/15/24 → 3/15/27 |
Funding
- Tempus Compass, LLC (Prot #IMM1104-101 // Prot #IMM1104-101)
- Immuneering Corporation (Prot #IMM1104-101 // Prot #IMM1104-101)
Prot #IMM1104-101: A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants with Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors
- Chandra, Sunandana (PD/PI)
Project: Research project